Generic Medicine Info
Active major bleeding. CrCl <30 mL/min and dialysis-dependent patients. Severe uncontrolled HTN; subacute bacterial endocarditis.
Special Precautions
Increased risk of potentially fatal thrombosis during brachytherapy procedure. Patients at high risk of serious bleeding; recent major surgery or puncture of large vessels or organ biopsy. Renal impairment. Pregnancy, lactation, elderly.
Adverse Reactions
Acute stent thrombosis, bleeding, ecchymosis, hypotension, HTN, headache, nausea, dyspepsia, insomnia, nervousness, anxiety, pelvic and abdominal pain, urinary retention, anaemia, thrombocytopaenia, inj site pain; rarely, thrombosis, tachycardia, bradycardia, vomiting, back pain, dyspnoea, fever.
Potentially Fatal: Anaphylaxis including anaphylactic shock.
Drug Interactions
May increase risk of bleeding when used w/ thrombolytics, oral anticoagulants or drugs that affect platelet function.
ATC Classification
B01AE06 - bivalirudin ; Belongs to the class of direct thrombin inhibitors. Used in the treatment of thrombosis.
Disclaimer: This information is independently developed by CIMS based on bivalirudin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in